
Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$17.92
+US$0.01 · +0.06%
AMRX公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Hold
Wait — insufficient conviction to act
估值
61
Undervalued
动量
67
Gaining
情绪
64
Bullish
风险韧性
66
Moderate Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
- 行业
- Drug Manufacturers - Specialty & Generic
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Chirag K. Patel
- 上市以来
- 2018年5月7日
- 雇员
- 8,700
市场位置
- 成交量
- 136.55万
- 0.72× 平均值
- 平均成交量
- 189.23万
- 日均成交量
- 市值
- 57.19亿 USD
- 贝塔
- 1.26
- 市场参考 1
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 63.74亿 USD
- 市盈率(TTM)
- 36×
- 市净率(TTM)
- 173.11×
- 市销率(TTM)
- 1.83×
- EV/EBITDA
- 10.56×
- 盈利收益率
- 1.82%
- 自由现金流收益率
- 6.84%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- 39.32%
- 营业利润率
- 12.93%
- 净利润率
- 5.05%
- 净资产收益率
- -101.78%
- 资产收益率
- 1.96%
- 投入资本回报率
- 13.80%
财务健康
- 负债权益比
- 84.54×
- 流动比率
- 2.17×
财报历史与展望
- EPS超预期率
- 91%
- 超预期10次、低于预期1次、符合预期0次
- 平均EPS意外幅度
- +35.72%
- 11 类似报告
- 最新每股收益结果
- 0.3
- 预期0.22 · 超预期34.83%
EPS:实际值与预期值
近期已公布业绩
营收:实际值与预期值
近期已公布业绩
分析师评级
第三方分析师预期可能变化,并非 GoAI 建议。
评级分布
17项评级近期分析师行动
AMRX同业公司
持有AMRX的ETF
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR1.93亿0.17%1111.89亿 USD0.06%US$147.31—
Vanguard Morningstar Total Stock Market ETFVTI1.02亿0.00%2.3万亿 USD0.03%US$378.24—
iShares Russell 2000 ETFIWM7806.58万0.10%816.21亿 USD0.19%US$299.96—
Vanguard Morningstar Small-Cap ETFVB7391.78万0.04%1834亿 USD0.03%US$304.76—
Vanguard Morningstar Small-Cap Value ETFVBR4693.49万0.07%683亿 USD0.05%US$249.18—
Vanguard Extended Market ETFVXF3631.86万0.04%937亿 USD0.05%US$245.53—
Invesco S&P SmallCap Momentum ETFXSMO3338.89万1.11%——US$86.05—
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2899.08万0.17%170.31亿 USD0.03%US$57.28—
iShares Core S&P Small-Cap ETFIJR- 市场价值
- 1.93亿
- 重量
- 0.17%
- AUM
- 1111.89亿 USD
- 费用率
- 0.06%
- 价格 / 1日
- US$147.31—
Vanguard Morningstar Total Stock Market ETFVTI- 市场价值
- 1.02亿
- 重量
- 0.00%
- AUM
- 2.3万亿 USD
- 费用率
- 0.03%
- 价格 / 1日
- US$378.24—
iShares Russell 2000 ETFIWM- 市场价值
- 7806.58万
- 重量
- 0.10%
- AUM
- 816.21亿 USD
- 费用率
- 0.19%
- 价格 / 1日
- US$299.96—
Vanguard Morningstar Small-Cap ETFVB- 市场价值
- 7391.78万
- 重量
- 0.04%
- AUM
- 1834亿 USD
- 费用率
- 0.03%
- 价格 / 1日
- US$304.76—
Vanguard Morningstar Small-Cap Value ETFVBR- 市场价值
- 4693.49万
- 重量
- 0.07%
- AUM
- 683亿 USD
- 费用率
- 0.05%
- 价格 / 1日
- US$249.18—
Vanguard Extended Market ETFVXF- 市场价值
- 3631.86万
- 重量
- 0.04%
- AUM
- 937亿 USD
- 费用率
- 0.05%
- 价格 / 1日
- US$245.53—
Invesco S&P SmallCap Momentum ETFXSMO- 市场价值
- 3338.89万
- 重量
- 1.11%
- AUM
- —
- 费用率
- —
- 价格 / 1日
- US$86.05—
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- 市场价值
- 2899.08万
- 重量
- 0.17%
- AUM
- 170.31亿 USD
- 费用率
- 0.03%
- 价格 / 1日
- US$57.28—
继续GoAI的研究
在 GoAI 中研究AMRXresearch.disclaimer





